Medical News Today: Study zeroes in on gut bacteria that may cause bowel cancer
New research uses Mendelian randomization and genetic data to study potential causal relations between certain types of gut bacteria and bowel cancer.
In conclusion, two molecular subtypes have been consistently identified in our series of CD-SBCs, a microsatellite instability-immune and a mesenchymal subtype, the former likely associated with an indolent and the latter with a worse tumor behavior.
People with an unclassified type of Bacteroidales bacteria in their guts may be at greater risk of developing colorectal cancer Related items fromOnMedica Invest in workforce to roll out bowel cancer screening, urges former health secretary Bowel cancer screening tests exceed target set in Scotland Taking aspirin with a PPI reduces risk of oesophageal cancer FOB associated with rise in all-cause mortality Screening for colorectal cancer should start at 45 years
There were 1.8million new cases of bowel cancer in 2017, up by 9.5 per cent over the last 27 years. Figures show 52,331 people were diagnosed with the disease in 2017 and 209,237 in the US.
ConclusionsPhysical and psychological functioning, pain, fatigue and appetite loss had prognostic significance above and beyond clinical predictors in CRC. Routine monitoring of these PROs may allow earlier detection and amelioration of problems, which may improve quality of life and perhaps extend survival. More research is needed to determine prognostic value of PROs in early-stage CRC, and prognostic significance of changes in PRO scores.
(CNN) — Leading nutritional experts in the United States and the UK are fired up about new dietary recommendations claiming there’s no need to reduce your red and processed meat intake for good health. “This is a very irresponsible public health recommendation,” said Dr. Frank Hu, who chairs the nutrition department at the Harvard T.H. Chan School of Public Health. The new guidelines and five corresponding studies are part of a systematic analysis of existing research done by NutriRECS, a recently formed international group of nutritionists and health researchers. NutriRECS says its mission is to &l...
A new study from the University of South Australia researchers found the number of people that die from bowel or colorectal cancer (CRC) would be much higher without pre-diagnostic colonoscopies. Now more than 700,000 people die from bowel cancer each year according to the university. The researchers from the Universityâs Cancer Epidemiology and Population Health looked at data from 12,906 bowel cancer patients that indicate the fecal occult blood testing (FOBT) with a follow-up colonoscopy plays a key role in catching the disease early before symptoms appear. Results show that having one pre-diagnostic c...
A new meta-review of several existing studies has found links between gut microbiome composition and trends in bowel cancer development.
Colorectal cancer is a preventable disease.1 Bowel cancer screening whether via fecal immunochemical testing, flexible sigmoidoscopy, or primary colonoscopy, decreases the risk of future colorectal cancer significantly, and colonoscopy is the final common pathway in screening to remove polyps and prevent cancer1,2; however, despite this effectiveness, it has also become evident that colonoscopy is not perfect and cancers occur after a “clear” colonoscopy at a rate of between 2.5% and 8.7% of the total cancers diagnosed, depending on the method used to calculate and the population.
AbstractPrevious studies have shown that a large proportion of women invited for bowel cancer screening prefer endoscopists of the same gender. We tested whether women who are initially disinclined to undergo flexible sigmoidoscopy screening would be more willing to have the test with a female practitioner if they were also offered a decoy appointment with a male practitioner. We conducted two online experiments with women aged 35 –54, living in England, who did not intend to undergo flexible sigmoidoscopy screening. In both experiments, women were randomised to two conditions: (1)control (appointment with a female e...
Patients with metastatic colorectal cancer who have a BRAF mutation have improved survival after treatment with three targeted therapies instead of standard chemotherapy, results from a phase III trial have shown.